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Abstract: Multiple Sclerosis (MS) is a chronic disease, but in rare fulminant cases rapid 
progression may lead to death shortly after diagnosis. Currently there is no diagnostic test 
to predict disease course. The aim of this study was to identify potential biomarkers/ 
proteins related to rapid progression. We present the case history of a 15-year-old male MS 
patient. Cerebrospinal fluid (CSF) was taken at diagnosis and at the time of rapid 
progression leading to the patient’s death. Using isobaric tag labeling and nanoflow liquid 
chromatography in conjunction with matrix assisted laser desorption/ionization time of 
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flight tandem mass spectrometry we quantitatively analyzed the protein content of two CSF 
samples from the patient with fulminant MS as well as one relapsing-remitting (RR) MS 
patient and one control headache patient, whose CSF analysis was normal. Seventy-eight 
proteins were identified and seven proteins were found to be more abundant in both 
fulminant MS samples but not in the RR MS sample compared to the control. These 
proteins are involved in the immune response, blood coagulation, cell proliferation and cell 
adhesion. In conclusion, in this pilot study we were able to show differences in the CSF 
proteome of a rapidly progressing MS patient compared to a more typical clinical form of 
MS and a control subject. 
Keywords: multiple sclerosis; fulminant; shotgun-proteomics; protein quantification; 
isobaric tag labeling; matrix assisted laser desorption/ionization time of flight tandem mass 
spectrometry (MALDI TOF/TOF MS) 
 
1. Introduction 
Multiple sclerosis is a demyelinative disorder of the central nervous system (CNS). The onset of the 
disease is in young adulthood in most cases, and although it usually does not decrease life expectancy 
it has a great impact on quality of life. As it affects patients in the most active period of their life it has 
a substantial socioeconomic burden as well. 
The etiology of the disease is still unknown. The typical disease course starts with a  
relapsing-remitting (RR) phase, with even complete remissions at the beginning and a gradual 
accumulation of residual symptoms over time. After a variable period of time (years-decades) the 
disease turns into a secondary progressive form characterized by a continuous progression with or 
without relapses. In 10–15 percent of cases the disease is progressive from the very beginning: primary 
progressive form. In very rare cases the disease course is fulminant and rapid progression leads to 
death shortly after diagnosis.  
Currently there is no available diagnostic test to predict disease course and prognosis in individual 
patients, therefore identification of biomarkers that at an early stage can differentiate between clinical 
forms and predict severity of the disease is of great importance. 
Over the last decade, proteomics has proven to be a powerful approach to gain insight into 
biological processes by monitoring the whole protein content of a certain sample at a distinct point of 
time. The major challenge in proteome analysis of complex biological samples like body fluids, such 
as plasma, cerebrospinal fluid (CSF) or urine, is to deal with the large dynamic range of the abundant 
proteins. Therefore, high resolving protein/peptide separation methods in combination with very 
accurate and high resolving mass spectrometric tools are essential for sensitive and significant protein 
identification [1–4]. However, differences in protein expression in clinical studies and their correlation 
to the disease are the main focus of interest [5]. Quantitative proteomic methods, like isobaric  
tag labeling, provide information about relative protein concentrations [6,7] and also allow for  
multiplexed approaches.  
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The aim of this study was to identify potential protein biomarkers in CSF related to rapid 
progression in multiple sclerosis using a differential shotgun-proteomic approach based on isobaric tag 
labeling and nanoLC-MALDI TOF/TOF MS. Although in recent years a number of papers appeared 
on proteomics of multiple sclerosis CSF, this is to the best of our knowledge the first report of a 
fulminant case combined with proteomic analysis of CSF. 
2. Results  
2.1. Experimental Design for MS Analysis 
The presented bottom up-strategy, based on isobaric tag labeling in conjunction with enzymatic 
digestion followed by nanoLC coupled off-line to MALDI TOF/TOF MS, has proven to be a powerful 
proteomic approach for quantitative protein profiling in complex biological samples. A satisfactory 
distribution of contingent precursor candidates for subsequent MS/MS experiments was achieved using 
the described protocol, which is essential for increasing sensitivity and thereby to enhance the protein 
identification rate (Figure 1).  
Figure 1. Mass chromatogram of one LC-MALDI experiment illustrating separation 
efficiency and hence improved sample complexity reduction. Two-dimensional survey of 
all TOF-MS spectra (x-axis) acquired from each collected fraction during peptide elution 
(y-axis, number of spectra and LC fractions, respectively). The values on the z-axis 
(rainbow-scale) indicate mass peak intensities in arbitrary units.  
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2.2. Protein-Identification by Combined Database Search  
The acquired LC-MS/MS data were combined in one data file and subjected to comprehensive 
database search following the mascot algorithm (www.matrixscience.com). Each protein was 
considered to be a positive match if it was identified by at least one MS/MS that fulfilled criteria of 
significance. The significance threshold was set to at least 99% (p < 0.01) and peptide uniqueness was 
required indicating identity or extensive homology.  
We have identified 78 proteins in the samples with a false positive identification rate of <2% 
(Supplementary Table S1). Among the findings, acute phase reactants and a large number of highly 
abundant proteins like albumin, immunoglobulins, apolipoproteins, hemoglobins, haptoglobin and 
transferrin were detected. Furthermore, some less abundant brain derived proteins including  
Limbic-system associated membrane protein and Neural cell adhesion molecule 1 were also identified. 
The findings further include transport proteins, immunoglobulins, glycoproteins, coagulation factors, 
complement factors, enzymes, inhibitors and structural/membrane-associated proteins. 
In order to validate the observed quantitative data, technical and biological replicate experiments 
were performed. Biological replicates included repeated processing (digestion and isobaric tag labeling) 
and analysis of the clinical samples. Technical replicates included repeated analysis of processed 
sample in order to evaluate precision of the technical platform. Here relative standard deviation values 
of 1%–23% for biological replicate experiments and values of 3%–8% for technical variation were 
observed [8].  
2.3. Differential Protein Profiles  
Isobaric tag labeling by means of iTRAQ was utilized for quantitative protein profiling. The main 
advantage of this approach is that the samples are analyzed under exactly the same conditions and the 
quantification is performed in the MS/MS mode. This limits the risk of systematic errors, increases the 
signal-to noise ratio (S/N) and results in a high reliability of the obtained data. Furthermore, a high 
sample throughput can be achieved because multiple samples are processed in parallel [7].  
Thirty proteins were found to be increased in at least one MS sample compared to the control 
sample (Table 1). Three proteins, hemoglobin alpha, beta and delta chains, were decreased in the 
multiple sclerosis samples compared to the headache patient control. This could potentially reflect a 
minor contamination due to puncture bleeding in the headache patient, but there were no visible signs 
of such contamination. In case of the remaining 48 proteins, we found no difference in abundance 
(Table 1, Supplementary Table S1). The biggest increase in abundance was observed for the following 
proteins: Ig kappa chain C region (IgK) (sample FM2), Osteopontin (OSTP) (FM2), Serum amyloid A 
protein (SAA) (FM2), Basement membrane-specific heparan sulfate proteoglycan core protein 
(PGBM) (FM1). Seven proteins were found to be up-regulated in both fulminant MS samples but not 
in the relapsing-remitting case compared to the control. These proteins included Ig kappa and  
gamma-1 chain C region, Complement C4-A, Fibrinogen beta chain, Serum amyloid A protein, Neural 
cell adhesion molecule 1 and Beta-2-glycoprotein 1 (Figure 2). 
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Table 1. List of proteins significantly up-regulated in at least one of the multiple sclerosis cerebrospinal fluid (CSF) samples compared to 
control. The relative abundance values are shown for RR (relapsing-remitting), FM1 (fulminant MS time point 1) and FM2 (fulminant MS 
time point 2) CSF samples compared to control (C), which is considered 1. + difference > 0.5; ++ difference > 1.0; +++ difference > 1.5. 
# Protein Name Database Entry a 
Mascot 
score b 
Number of 
Pep. c 
MW d Function C RR Δ FM1 Δ FM2 Δ 
 Transport proteins 
1 Serotransferrin  TRFE_HUMAN 1053 47 87.3411 Iron transport 1 1.171  1.61 + 1.16  
2 Apolipoprotein E  APOE_HUMAN 560 26 38.2412 Lipid transport 1 1.462  1.86 + 1.24  
3 Apolipoprotein A-IV  APOA4_HUMAN 37 6 49.5504 Lipid metabolism 1 1.52 + 1.31  1.98 + 
4 Phospholipid transfer protein PLTP_HUMAN 46 3 57.4823 Lipid transport 1 1.611 + 1.75 + 1.28  
 Immunoglobulins 
5 Ig gamma-3 chain C region  IGHG3_HUMAN 51 6 36.36 Immune response 1 1.544 + 1.47  1.61 + 
6 Ig kappa chain C region  KAC_HUMAN 464 8 13.0366 Immune response 1 1.38  1.63 + 2.56 +++ 
7 Ig kappa chain V-I region KV108_HUMAN 74 4 12.3321 Immune response 1 0.992  1.27  1.54 + 
8 Ig lambda chain C regions  LAC_HUMAN 170 5 12.6644 Immune response 1 1.572 + 1.31  2.02 ++ 
9 Ig gamma-1 chain C region  IGHG1_HUMAN 210 9 40.676 Immune response 1 1.426  1.55 + 1.64 + 
10 Ig mu chain C region  MUC_HUMAN 233 11 53.3918 Immune response 1 1.848 + 1.65 + 1.83 + 
11 Ig heavy chain V-III region TUR  HV318_HUMAN 54 3 13.0917 Immune response 1 2.114 ++ 1.52 + 1.58 + 
 Glycoproteins 
12 Osteopontin  OSTP_HUMAN 462 7 38.4212 Cell communication 1 1.644 + 1.49  3.39 +++ 
13 Vitronectin VTNC_HUMAN 28 4 57.9411 Cell communication 1 1.574 + 1.78 + 1.38  
14 Zinc-alpha-2-glycoprotein precursor  ZA2G_HUMAN 47 2 37.061 
Cell adhesion. lipid 
degradation 
1 2.024 ++ 1.51 + 1.53 + 
15 Beta-2-glycoprotein 1  APOH_HUMAN 47 2 43.7975 
Regulation of blood 
coagulation 
1 1.341  1.53 + 1.64 + 
16 SPARC-like protein 1 precursor  SPRL1_HUMAN 85 3 82.6318 Calcium ion binding 1 1.677 + 1.82 + 1.44  
17 Chitinase-3-like protein 1  CH3L1_HUMAN 78 5 46.0906 Tissue remodeling 1 1.334  1.62 + 1.38  
 Coagulation factors 
18 Fibrinogen beta chain  FIBB_HUMAN 165 8 61.7759 Cell proliferation 1 1.416  1.83 + 1.89 + 
19 Fibrinogen alpha chain  FIBA_HUMAN 156 8 101.853 Cell proliferation 1 1.073  0.97  1.88 + 
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Table 1. Cont. 
 Complement factors 
20 Complement factor B  CFAB_HUMAN 28 4 94.3637 Immune response 1 1.725 + 1.97 + 1.26  
21 Complement C4-A  CO4A_HUMAN 339 27 205.178 Immune response 1 1.474  1.68 + 1.63 + 
 Enzymes 
22 Elongation factor 2 kinase  EF2K_HUMAN 29 4 88.2004 
Translational 
elongation 
1 1.642 + 2.35 ++ 1.16  
23 Prostaglandin-H2 D-isomerase  PTGDS_HUMAN 216 11 22.7844 Enzyme activity 1 1.178  1.59 + 1.03  
24 Cystatin-C  CYTC_HUMAN 249 12 17.1259 Enzyme regulator 1 1.53 + 2.11 ++ 1.57 + 
 Structural/membrane asssociated 
25 Calsyntenin-1  CSTN1_HUMAN 90 3 117.941 Signal transduction 1 1.596 + 2.21 ++ 1.62 + 
26 
Limbic system-associated 
membrane protein precursor  
LSAMP_HUMAN 73 1 40.3779 
Cell adhesion. 
neuronal growth 
1 2.205 ++ 2.37 ++ 1.79 + 
27 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein  
PGBM_HUMAN 39 5 487.116 Protein binding 1 2.014 ++ 2.8 +++ 2.06 ++ 
28 Neural cell adhesion molecule 1.  NCA11_HUMAN 71 2 102.35 Cell adhesion 1 1.451  1.77 + 1.53 + 
29 
Monocyte differentiation antigen 
CD14 
CD14_HUMAN 27 5 41.9976 Immune response 1 1.569 + 1.846 + 1.88 + 
 Miscellaneous 
30 Serum amyloid A protein  SAA_HUMAN 87 2 14.4341 
Acute phase 
response 
1 1.27  1.59 + 2.58 +++ 
a Uniprot knowledgebase entry; b Mascot protein score revealed by MudPIT scoring. Proteins were found and identified by integrated mascot database batch search of all 
MS/MS in Swissprot v 51.6. All matches are identified significantly. Identified proteins are considered as positive match on at least a 99% significance level (p < 0.01) 
corresponding to a significance threshold ionscore of 34; c Number of tryptically peptides that match the identified protein. At least one matching peptide for each 
identified protein must fulfil criteria of significance (p < 0.01) and uniqueness; d Molecular weight in kDa. 
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Figure 2. Proteins more abundant in both fulminant Multiple Sclerosis (MS) samples but 
not in relapsing-remitting (RR) MS compared to control: Ig kappa chain C region (KAC). 
Complement C4-A (CO4A). Ig gamma-1 chain C region (IGHG1). Fibrinogen beta chain 
(FIBB). Serum amyloid A protein (SAA). Neural cell adhesion molecule 1 (NCA11).  
Beta-2-glycoprotein 1 (APOH). Error bars represent the standard deviation (n = number of 
significantly identified peptides that provide significant quantitative information). 
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Figure 2. Cont. 
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Ig kappa chain C region and Ig gamma-1 chain C region are proteins making up the constant 
regions of immunoglobulins [9]. This region is invariable in its amino acid sequence within any class 
of immunoglobulin.  
Complement C4 has a central role in the activation of the classical pathway of the complement 
system [9]. Activated C1 removes the C4a anaphylatoxin from the alpha chain. It is a mediator of local 
inflammatory process, induces the contraction of smooth muscle, increases vascular permeability and 
causes histamine release from mast cells and basophilic leucocytes. Also, it is a blood group antigen. 
Fibrinogen contains 2 sets of 3 non-identical chains (alpha, beta, and gamma) [9]. In the process of 
blood coagulation, conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves 
fibrinopeptides A and B from alpha and beta chains. 
Beta-2-glycoprotein 1 binds to various negatively charged substances, such as heparin and 
phospholipids. It may prevent the activation of the intrinsic blood coagulation cascade by binding to 
phospholipids on the surface of damaged cells. 
Serum amyloid A protein is a major acute phase reactant. In reactive, secondary amyloidosis SAA 
protein accumulates in the extracellular space of various tissues. These deposits alter tissue structure 
and interfere with normal function. 
Neural cell adhesion molecule 1 is a cell membrane protein [9]. It is involved in neuron-neuron 
adhesion, neurite fasciculation and outgrowth of neurites.  
3. Discussion  
In this report we present the application of a rapid, quantitative proteomic analysis for identifying 
differentially expressed proteins in the CSF of a fulminant multiple sclerosis patient and control samples. 
In recent years a number of papers appeared describing proteomic analysis of CSF or brain tissue of 
multiple sclerosis patients [10–14]. The clinical characteristics of the samples as well as the methods 
used in these studies are rather diverse, making their comparison very difficult. 
Hammack et al. [10] reported the analysis of a pooled sample of three relapsing-remitting MS 
patients and a pooled sample of three patients with non-MS inflammatory CNS disorders using  
two-dimensional gel electrophoresis and peptide mass fingerprinting. They identified four proteins in 
the gels containing MS CSF that were not reported previously in normal human CSF: CRTAC-1B 
(cartilage acidic protein), tetranectin (a plasminogen-binding protein), SPARC-like protein (a calcium 
binding cell signalling glycoprotein) and autotaxin t (a phosphodiesterase). Among these, tetranectin 
and SPARC-like protein were identified in our samples as well, and were found to be elevated in the 
RR and the FM1 sample. 
In the study of Dumont et al. [11] CSF samples from five MS patients (4 RR, one secondary 
progressive) were analyzed by two-dimensional gel electrophoresis followed by liquid 
chromatography tandem mass spectrometry. With this method 15 proteins have been identified that 
were not previously observed on non-multiple sclerosis CSF 2-DE gels. These proteins were: 
psoriasin, calmodulin-related protein NB-1, annexin 1, EWI-2, Niemann-Pick disease type C2 protein 
(NPC-2), semenogelin 1 (SEM1), semenogelin 2 (SEM2), complement factor H-related protein 1 
(FHR-1), procollagen C-proteinase enhancer protein (PCPE), aldolase A, N-acetyllactosaminide  
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β-1,3-N-acetylglucosaminyl-transferase, tetranectin, cystatin A, superoxide dismutase 3 and 
glutathione peroxidase (Supplementary Table S1). 
Lehmensiek et al. [12] compared CSF samples from RR MS and clinically isolated syndrome (CIS) 
patients with controls using two-dimensional difference gel electrophoresis (2-D-DIGE) and  
MALDI-TOF mass spectrometry. In RR MS Ig kappa chain NIG93 protein was increased in 
concentration, while transferrin isoforms, alpha 1 antitrypsin isoforms, alpha 2-HS glycoprotein, Apo 
E and transthyretin decreased. In our study transferrin was found to be more abundant in the FM1 
sample but not in the other fulminant and the RR sample. Apo E showed the same pattern. In contrast, 
transthyretin showed no change compared to the control.  
In a recently published study of Stoop et al. [13] significant differences were observed comparing 
the peak lists of spectra from CSF of MS patients and patients with other neurological diseases (OND), 
and also clinically isolated syndrome (CIS) vs. OND. Three differentially expressed proteins were 
identified in the CSF of MS patients compared to CSF of patients with OND: chromogranin A, 
clusterin and complement C3. 
The same group compared proteome profiles of CSF from RR and primary progressive (PP) 
multiple sclerosis and found that they overlap to a large extent [15]. The main detected difference was 
that protein jagged-1 was less abundant in PP MS compared to RR MS, while vitamin D-binding 
protein was only detected in the RR MS CSF samples. Ottervald et al. found an increased CSF level of 
vitamin-D-binding protein in SP MS compared to the control [16]. In our samples this protein was 
detected, but there was no significant difference across the samples, probably due to the fact that we 
did not analyze CSF from progressive clinical forms of the disease. Recently, impaired vitamin D 
homeostasis has been linked to multiple sclerosis [17]: high serum levels of 25-hydroxyvitamin D 
correlated with a reduced risk of MS [18] and Vitamin D supplementation was proposed as an add-on 
therapy [19]. 
In our study among the seven proteins found to be more abundant in fulminant MS, fibrinogen and 
β-2-glycoprotein 1 are involved in the process of blood coagulation. Interestingly, in a study 
examining the proteomics of multiple sclerosis lesions Han et al.  [14] identified several proteins 
involved in coagulation that were uniquely found in chronic active plaque samples: tissue factor, 
protein C inhibitor, thrombospondin, fibronectin and vitronectin. This finding suggested dysregulation 
of molecules associated with coagulation. In further experiments both tissue factor and activated 
protein C administration ameliorated disease severity in experimental autoimmune encephalomyelitis 
(EAE), an animal model of multiple sclerosis. 
Fibrinogen, which was found to be up-regulated in our study in the CSF of the fulminant MS 
patient, was shown to be deposited perivascularly in MS plaques [20]. Blood-brain-barrier disruption, 
a common feature in MS lesions permits the leakage of fibrinogen into the CNS. Fibrinogen induces 
the differentiation of microglia to phagocytes via the integrin receptor Mac-1 [20]. Microglia 
activation leads to phagocytosis and tissue damage in inflammatory demyelination. In the study of 
Adams et al. a fibrin-derived γ377–395 peptide was able to inhibit fibrinogen-Mac-1 interaction and 
microglia activation without affecting the procoagulant properties of fibrinogen [20]. The peptide was 
found to ameliorate symptoms of mice with EAE, therefore it may be a novel therapeutic strategy  
for MS. 
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Serum amyloid A protein had an elevated level in both fulminant samples. In earlier studies it was 
shown to be elevated in the serum of RR multiple sclerosis patients [21], and also a transient increase 
of SAA was observed after intramuscular interferon-β 1a administration [22]. 
From the up-regulated proteins in fulminant MS, immunoglobulin and complement proteins take 
part in inflammation and immune response. Their elevated level in CSF may account for the rapid 
progression of the disease.  
In histopathological studies, multiple sclerosis lesions are grouped in four types based on 
immunocytochemical characteristics of demyelination patterns [23]. Pattern II lesions are characterized 
by antibody-complement mediated damage. Considering our case, there are regions showing 
characteristics of pattern II demyelination. In a recent immunohistochemical study Mahad et al. [24] 
analyzed mitochondrial respiratory chain proteins in active lesions from acute fulminant multiple 
sclerosis (pattern II and pattern III lesions) and white matter stroke cases containing lesions with active 
demyelination. In pattern II lesions in the early active stage they observed perivenous sheaths of 
demyelination separated by areas of partly preserved myelin with abundant macrophages, containing 
early myelin degradation products. At higher magnification, the tissue in early active and late active 
stages appears vacuolated, due to profound edema, which extends into the adjacent normal white 
matter. This histological description (and also the slides in the paper) is strikingly similar to our case, 
confirming the assumption that the lesions seen in our fulminant case belong to pattern II  
type demyelination.  
4. Experimental Section  
4.1. Patient Case History and Outcome 
A 15-year-old male patient was admitted to the Department of Neurology, University of Szeged, 
Hungary, in November 2004, since two days after a Hepatitis-B vaccination his right limbs became 
weak and developed movement coordination problems. His disease started in March 2004, when he 
was admitted to a pediatric department because of dizziness and vomiting. During his observation 
muscle weakness developed on his right extremities, with vestibular and cerebellar symptoms. Brain 
magnetic resonance imaging (MRI) showed multiple contrast-enhancing white-matter lesions. In 
September 2004 he was admitted to hospital with left lower limb weakness and cerebellar symptoms. 
His symptoms improved.  
4.1.1. Examinations 
Cerebrospinal fluid (CSF) analysis showed a protein content of 0.57 g/L (determined by laser 
nephelometry), wbc (white blood cell count): 15 × 106 cells/L, rbc (red blood cell count): 8 × 106 cells/L. 
Albumin quotient (Qalb) of 7.7 indicated an intact blood brain barrier (BBB). The IgG index was 
elevated (0.74). The immunoblot was positive for IgG and oligoclonal IgG bands were found with 
isoelectric focusing (Figure 3). 
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Figure 3. Immunoblot of CSF from a fulminant multiple sclerosis patient at two different 
time points; (A) (FM1) and (B) (FM2). 
 
4.1.2. Electrophysiology 
Somatosensory Evoked Potentials (SSEP) showed severe central conduction damage (increased 
central conduction times) and findings characteristic of brainstem and subcortical lesions. According 
to McDonald’s criteria [25] the patient was diagnosed as suffering from multiple sclerosis with  
relapsing-remitting clinical form. The patient had his fourth relapse in January 2005. He had 4 relapses 
in 1 year, so it was decided to put him on immunomodulatory treatment (interferon-β 1b sc., every 
other day). Despite the immunomodulatory treatment he had 4 more relapses in 2005 and a continuous 
progression of the disease was observed. The EDSS score (Expanded Disability Status Scale [26]) was 
3.5 points. A second brain MRI was performed. Compared to the first MRI the number and size of 
lesions increased. There were lesions in the pons, cerebellum on both sides, frontal and temporal white 
matter, parietal subcortical region and capsula interna (Figure 4A,B). In 2006 after recurrent urinary 
infections the patient became unable to walk. On admission neurological examination showed ptosis 
on the right, internuclear ophtalmoparesis and tetraparesis. He had a permanent catheter due to urine 
retention. The EDSS score was 8 points. On the 6th day of observation the patient became cyanotic 
and had periodic breathing. He was intubated and transferred to the Intensive Care Unit (ICU). The 
second lumbar puncture (LP) was performed to exclude meningitis. The protein content was 0.68 g/L, 
wbc: 80× 106 cells/L, 95% lymphocytes (ly), 5% monocytes (mo), rbc: 810× 106 cells/L. The albumin 
index was elevated (12.9), indicating a BBB (blood brain barrier) damage. The IgG index was also 
highly elevated, 1.88. Oligoclonal bands were found (Figure 3B). Results showed inflammation and 
increased cell count, but microbiological examinations of the CSF excluded meningitis. The disease 
spread to the hypothalamus: he had polyuria with 18 L/day urine volume. Because of recurring 
infections of the airways and urinary tract he was treated with antibiotics based on microbiological 
examinations. After a one month treatment in the ICU the patient died. Urosepsis or candida sepsis 
was presumed as the immediate cause of death. 
4.1.3. Pathology 
In coronal sections of the formalin fixed brain and spinal cord no specific macroscopic features 
were observed including plaques or atrophy. Histologically widespread myelin loss was observed in 
the brainstem and optic chiasm. Widespread perivascular and scattered interstitial lymphocytes were 
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also detected. To detect the myelin loss luxol fast blue staining was used (Figure 5A,B). Furthermore, 
perivascular and scattered interstitial lymphocytes were also observed using lymphocyte PAN T, B 
markers (CD3, CD20). Considering the clinical features and pathological findings the diagnosis of 
multiple sclerosis was made. The cause of death was severe bronchopneumonia. 
Figure 4. Brain MRI. (A) 2006 T1 Sagittal; (B) 2006 T2 Flair. 
(A) (B) 
Figure 5. Brainstem: a luxol fast blue violet stain shows loss of myelin (B) in comparison 
to a normal myelinated area (A). A: magnification 10×; B: magnification 20×. 
(A) (B) 
4.2. Sampling 
CSF samples were obtained from diagnostic lumbar puncture at the Department of Neurology, 
University of Szeged, Hungary. Samples were immediately frozen, transported on dry ice to the 
Department of Physical and Analytical Chemistry, Analytical Chemistry, Uppsala University, Sweden, 
and stored at −80 °C until analysis. CSF samples from a fulminant case of multiple sclerosis taken at 
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two different time points were analyzed: at the time of diagnosis (FM1) and later at the time of rapid 
progression of the disease (FM2). We chose a CSF sample from a patient with relapsing-remitting 
(RR) clinical form of the disease (disease control) who has an EDSS score of only 2 points after  
20 years duration of the disease, indicating a good functional status, and a CSF sample from a 
headache patient whose diagnostic CSF analysis proved to be normal (healthy control). Table 2 shows 
demographic and clinical data of the multiple sclerosis and control subjects. 
Table 2. Demographical and clinical data of multiple sclerosis patients and controls. 
 Age (years) Gender Duration of the disease EDSS 
Fulminant MS t1 15 M 8 months 5 
Fulminant MS t2 16 M 22 months 8 
RR MS 25 F 20 years 2 
Control 23 M NA NA 
RR = relapsing-remitting, t1 = 1st lumbar puncture, t2 = 2nd lumbar puncture, M = male, F = female,  
EDSS = Expanded Disability Status Scale [26], NA = not applicable. 
4.3. Ethics 
The study was approved by the Human Investigation Review Board of the University of Szeged, 
Albert Szent-Györgyi Clinical Centre and it agrees with the Declaration of Helsinki (Ethical 
permission # 93/2007).  
4.4. Chemicals and Reagents 
Acetonitrile (ACN), methanol (MeOH), acetic acid (HAc), ammonium-dihydrogen-phosphate, 
phosphoric acid and sodium hydroxide were obtained from Merck (Darmstadt, Germany). Urea and 
trifluoroacetic acid (TFA) were purchased from Sigma Aldrich (St. Louis, MO, USA). High purity 
water was taken from a Milli-Q (Millipore, Bedford, MA, USA) purification system. 
4.5. Protein Digestion and Isobaric Tag Labeling Procedure 
Four samples were chosen for quantitative protein analysis by isobaric tag labeling using the 
iTRAQ 4plex kit (Applied Biosystems, Foster City, CA, USA). The procedure was followed according 
to the manufacturers’ instructions. The protocol is described in detail elsewhere [27]. Briefly, for each 
sample, a volume corresponding to 100 µg total protein (as determined by Bradford protein assay) was 
aliquoted. The normalized samples were individually subjected to reduction and alkylation prior 
enzymatic digestion for 24 h with trypsin. Each sample was subsequently labeled with iTRAQ  
114–117 and samples were combined for multiplexed LC MS/MS analysis.  
4.6. Liquid Chromatography–Mass Spectrometry  
Nanoscale liquid chromatography coupled to MALDI mass spectrometry experiments were 
performed as described previously [27]. Briefly, an amount of 1.5 μg labelled and combined protein 
digestion products were analyzed using a 1100 nanoflow LC system equipped with a micro fraction 
collector (Agilent Technologies, Waldbronn, Germany). Peptide gradient elution was followed by 
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direct fractionation onto a MALDI target plate (disposable PAC target, Bruker Daltonics, Bremen 
Germany) resulting in 384 fractions. The targets were washed with 10 mM NH4H2PO4/0.1% TFA after 
sample application and before subjection to the mass spectrometer. The detailed protocol for mass 
spectrometry based protein identification is described in detail elsewhere [8]. Briefly, peptide mass 
data were acquired with an Ultraflex II MALDI-TOF/TOF MS (Bruker Daltonics, Bremen, Germany) 
in reflector positive mode. Data acquisition was assisted by the WarpLC Software (Bruker Daltonics) 
for automatic TOF-MS spectra acquisition, background signal filtering, grouping of intact peptide 
signals into a peptide profile with respect to their distribution and intensity as well as optimized 
precursor ion selection for subsequent MS/MS experiments. For final protein identification all MS/MS 
data were analyzed in a comprehensive MS/MS ion search using the Mascot search engine  
(v 2.2, Matrix Science, London, UK). The relative abundance of proteins in the 3 MS samples  
(FM1, FM2, RR) was expressed as ratios compared to the control sample. The measurement was 
repeated to show reproducibility of the method. A difference in abundance of 0.5 or above was 
determined to be significant prior to data analysis. The difference in relative abundance of >0.5 was 
marked with “+”, more than 1.0 with “++” and more than 1.5 with “+++” [28]. 
5. Conclusions  
Our study found a number of proteins that may have a role in rapid disease progression in multiple 
sclerosis. Further studies are needed to relate the function of these proteins to disease pathology. 
Current diagnostic CSF tests examine the presence of oligoclonal bands and IgG index to support the 
diagnosis of MS [29]. Proteomic studies of CSF may lead to the development of more specific 
biomarkers that will allow earlier diagnosis and distinction between clinical forms of the disease. The 
search for biomarkers that are able to identify patients at high risk for rapid progression becomes 
increasingly important with the appearance of more aggressive treatment possibilities. The 
shortcoming of our study is the small sample size. In another ongoing study we currently analyze  
LC-FTICR MS [30–32] data of a larger set of CSF samples from a variety of clinical forms of MS and 
matched controls.  
Despite the increasing number of studies investigating potential biomarkers of MS disease 
progression and response to therapy, there is still no protein that is repeatedly identified by different 
groups. This may be due to the relatively small sample sizes and the heterogeneity of the methods 
applied. Large scale multi-center projects using standard methods for collecting, storing and analyzing 
the samples are necessary to validate these preliminary results and integrate candidate biomarkers into 
the pathomechanism of the disease.  
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